Genmab: shares edge higher after Darzalex sales report
(CercleFinance.com) - Shares of Genmab were up slightly on the Nasdaq Copenhagen market on Wednesday after the Danish biotech firm announced that worldwide net sales of Darzalex, as reported by US partner Johnson & Johnson, reached 511 million dollars in the second quarter of 2018.
By comparison, consensus was aiming at sales of just 469 million dollars for the quarter.
Net sales were 298 million dollars in the US and 213 million dollars in the rest of the world, Genmab said.
As a reminder, Genmab receives royalties on the sales of Darzalex, a monoclonal antibody for the treatment of patients with multiple myeloma, under an exclusive worldwide license with J&J's Janssen Biotech.
Shares in Genmab are currently up 1.6% at 1,132.5 Danish kroner.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
By comparison, consensus was aiming at sales of just 469 million dollars for the quarter.
Net sales were 298 million dollars in the US and 213 million dollars in the rest of the world, Genmab said.
As a reminder, Genmab receives royalties on the sales of Darzalex, a monoclonal antibody for the treatment of patients with multiple myeloma, under an exclusive worldwide license with J&J's Janssen Biotech.
Shares in Genmab are currently up 1.6% at 1,132.5 Danish kroner.
Copyright (c) 2018 CercleFinance.com. All rights reserved.